Why Cetuximab is Not Active in the Adjuvant Setting
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Joseph C. Murray & Christina S. Wu & Louis M. Weiner
- چاپ و سال / کشور: 2011
Description
Cetuximab—a humanized monoclonal antibody targeting EGFR—can extend progression-free survival in patients with metastatic colorectal cancer. EGFR network signal perturbation likely represents the predominant mechanism of action of cetuximab, while immune effector cell-mediated antibody-dependent cellular cytotoxicity appears to be relevant as well. KRAS mutation status has proven to be an important predictive biomarker for cetuximab therapy as cetuximab is ineffective in patients with well-defined mutations. Given the success of anti- EGFR antibody therapy in metastatic disease, a recent phase 3 clinical study was devised to assess the efficacy of cetuximab in the adjuvant setting. Unexpectedly, cetuximab did not demonstrate enhanced survival when used in combination with adjuvant chemotherapy, even when KRAS status was known. Herein, we provide our hypotheses as to why cetuximab is not active in the adjuvant setting, discussing both known and potential mechanisms of resistance to anti-EGFR therapy.
Curr Colorectal Cancer Rep (2011) 7:211–217 DOI 10.1007/s11888-011-0103-4 Published online: 25 June 2011
